
Evommune Inc (EVMN) Stock Forecast & Price Target
Evommune Inc (EVMN) Analyst Ratings
Bulls say
Evommune is attractive fundamentally because it combines a relatively modest ~$290MM market cap with a pro-forma cash balance of about $290MM, giving it runway into 2H29 and reducing near-term financing risk. The company’s pipeline also has multiple shots on goal, led by EVO301, which showed promising Phase 2a proof-of-concept in atopic dermatitis and is advancing to a Phase 2b dose-ranging trial in mid-2027, while additional studies in ulcerative colitis and other inflammatory settings expand its addressable opportunity. Further upside comes from EVO570’s in-licensed, highly differentiated oral VAV1 degrader profile—sub-nanomolar potency, high selectivity, durable degradation, and QD dosing potential—which supports a credible path to meaningful value creation across 2027 clinical catalysts.
Bears say
Evommune is increasingly a single-asset story after EVO756 failed to show differentiation from placebo in phase 2b CSU and AD, with no meaningful efficacy signal on itch or EASI and the program now assigned no value by the cited analysis. The company has no marketed products, faces substantial regulatory and execution risk, and must still prove EVO301 in ulcerative colitis and other settings despite a cash-adjusted enterprise value of about $185 million and cash runway only extending into 2029. With escalating R&D spending, no demonstrated subcutaneous translation for IL-18, and a highly competitive AD landscape, the business remains vulnerable to further downside if future data fail to produce clear efficacy, safety, or commercialization advantages.
This aggregate rating is based on analysts' research of Evommune Inc and is not a guaranteed prediction by Public.com or investment advice.
Evommune Inc (EVMN) Analyst Forecast & Price Prediction
Start investing in Evommune Inc (EVMN)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Evommune Inc (EVMN) Forecast
Evommune Inc (EVMN) Analyst Forecast & Price Prediction
Start investing in Evommune Inc (EVMN)
Order type
Buy in
Order amount
Est. shares
0 shares